Treatment Response to Lycopene in Recurrent Prostate Cancer Confirmed on ¹⁸F-Fluciclovine PET/CT

F-18-fluciclovine (Axumin; Blue Earth Diagnostics, Ltd, Oxford, United Kingdom) PET has shown value in detecting biochemical recurrent prostatic cancer. Lycopene, a plant-based carotenoid, is reported to have potential inhibitory effect on prostate cancer, as a complementary treatment. We report a case of biochemically recurrent prostate cancer showing treatment response to lycopene as seen on an F-18-fluciclovine PET/CT correlating with serum prostate-specific antigen response.